Biomarin Pharmaceutical Inc (BMRN)

Return on assets (ROA)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 426,859 322,291 256,589 205,455 167,645 147,021 99,991 71,615 141,561 83,912 54,070 39,347 -64,080 10,846 832,143 790,019 854,029 852,025 122,258 114,006
Total assets US$ in thousands 6,988,940 6,851,200 7,067,120 6,872,670 6,841,600 6,758,160 6,563,170 6,433,700 6,375,070 6,264,040 6,145,840 6,062,710 6,004,770 5,977,480 5,898,500 5,805,050 5,848,020 6,158,090 5,302,110 4,722,840
ROA 6.11% 4.70% 3.63% 2.99% 2.45% 2.18% 1.52% 1.11% 2.22% 1.34% 0.88% 0.65% -1.07% 0.18% 14.11% 13.61% 14.60% 13.84% 2.31% 2.41%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $426,859K ÷ $6,988,940K
= 6.11%

The return on assets (ROA) for Biomarin Pharmaceutical Inc has shown fluctuations over the quarters analyzed. Starting at 2.41% in March 2020, the ROA dipped slightly to 2.31% by June 2020 before significantly increasing to 13.84% by September 2020. The upward trend continued, with ROA reaching 14.60% by December 2020 and remaining relatively stable around 13-14% until March 2021.

Subsequently, there was a noticeable decline in ROA to 0.18% by September 2021, with a further decrease to -1.07% by December 2021, indicating a period of reduced profitability in relation to the assets employed. However, the ROA recovered slightly to 0.65% by March 2022 and continued to improve, reaching 6.11% by December 2024.

Overall, the ROA trend for Biomarin Pharmaceutical Inc demonstrates variability but with an overall upward trajectory from 2020 to 2024, indicating the company's effectiveness in generating profits relative to its assets, albeit with some periods of lower performance interspersed.